“Twenty years on: the impact of fragments on drug discovery”. Nature Reviews. Drug Discovery15 (9): 605–619. (September 2016). doi:10.1038/nrd.2016.109. PMID27417849.
“Vemurafenib: the first drug approved for BRAF-mutant cancer”. Nature Reviews. Drug Discovery11 (11): 873–86. (November 2012). doi:10.1038/nrd3847. PMID23060265.
“Protein kinases 6. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification”. FASEB Journal9 (8): 576–96. (May 1995). doi:10.1096/fasebj.9.8.7768349. PMID7768349.
. Cancer Genome Project“Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF”. Cell116 (6): 855–67. (March 2004). doi:10.1016/S0092-8674(04)00215-6. PMID15035987.
“[2] Protein kinase catalytic domain sequence database: Identification of conserved features of primary structure and classification of family members”. Protein kinase catalytic domain sequence database: identification of conserved features of primary structure and classification of family members. Methods in Enzymology. 200. (1991). pp. 38–62. doi:10.1016/0076-6879(91)00126-H. ISBN9780121821012. PMID1956325
“Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers”. The Journal of Clinical Endocrinology and Metabolism88 (9): 4393–7. (September 2003). doi:10.1210/jc.2003-030305. PMID12970315.
“BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer”. Clinical Cancer Research10 (1 Pt 1): 191–5. (January 2004). doi:10.1158/1078-0432.CCR-1118-3. PMID14734469.
“Determinants of BRAF mutations in primary melanomas”. Journal of the National Cancer Institute95 (24): 1878–90. (December 2003). doi:10.1093/jnci/djg123. PMID14679157.
“BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas”. The Journal of Clinical Endocrinology and Metabolism89 (5): 2414–20. (May 2004). doi:10.1210/jc.2003-031425. PMID15126572.
“BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study”. The Journal of Clinical Endocrinology and Metabolism93 (10): 3943–9. (October 2008). doi:10.1210/jc.2008-0607. PMID18682506.
“Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885”. Cancer Research66 (23): 11100–5. (December 2006). doi:10.1158/0008-5472.CAN-06-2554. PMID17145850.
“Negative regulation of the serine/threonine kinase B-Raf by Akt”. The Journal of Biological Chemistry275 (35): 27354–9. (September 2000). doi:10.1074/jbc.M004371200. PMID10869359.
“Biochemical analysis of MEK activation in NIH3T3 fibroblasts. Identification of B-Raf and other activators”. The Journal of Biological Chemistry270 (13): 7644–55. (March 1995). doi:10.1074/jbc.270.13.7644. PMID7706312.
“Cell type-specific regulation of B-Raf kinase by cAMP and 14-3-3 proteins”. The Journal of Biological Chemistry275 (41): 31921–9. (October 2000). doi:10.1074/jbc.M003327200. PMID10931830.
“Complete coding sequence of a human B-raf cDNA and detection of B-raf protein kinase with isozyme specific antibodies”. Oncogene5 (12): 1775–80. (December 1990). PMID2284096.
“B-raf and a B-raf pseudogene are located on 7q in man”. Oncogene7 (4): 795–9. (April 1992). PMID1565476.
“Twenty years on: the impact of fragments on drug discovery”. Nature Reviews. Drug Discovery15 (9): 605–619. (September 2016). doi:10.1038/nrd.2016.109. PMID27417849.
“Vemurafenib: the first drug approved for BRAF-mutant cancer”. Nature Reviews. Drug Discovery11 (11): 873–86. (November 2012). doi:10.1038/nrd3847. PMID23060265.
“Protein kinases 6. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification”. FASEB Journal9 (8): 576–96. (May 1995). doi:10.1096/fasebj.9.8.7768349. PMID7768349.
. Cancer Genome Project“Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF”. Cell116 (6): 855–67. (March 2004). doi:10.1016/S0092-8674(04)00215-6. PMID15035987.
“[2] Protein kinase catalytic domain sequence database: Identification of conserved features of primary structure and classification of family members”. Protein kinase catalytic domain sequence database: identification of conserved features of primary structure and classification of family members. Methods in Enzymology. 200. (1991). pp. 38–62. doi:10.1016/0076-6879(91)00126-H. ISBN9780121821012. PMID1956325
“Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers”. The Journal of Clinical Endocrinology and Metabolism88 (9): 4393–7. (September 2003). doi:10.1210/jc.2003-030305. PMID12970315.
“BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer”. Clinical Cancer Research10 (1 Pt 1): 191–5. (January 2004). doi:10.1158/1078-0432.CCR-1118-3. PMID14734469.
“Determinants of BRAF mutations in primary melanomas”. Journal of the National Cancer Institute95 (24): 1878–90. (December 2003). doi:10.1093/jnci/djg123. PMID14679157.
“BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas”. The Journal of Clinical Endocrinology and Metabolism89 (5): 2414–20. (May 2004). doi:10.1210/jc.2003-031425. PMID15126572.
“BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study”. The Journal of Clinical Endocrinology and Metabolism93 (10): 3943–9. (October 2008). doi:10.1210/jc.2008-0607. PMID18682506.
“Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885”. Cancer Research66 (23): 11100–5. (December 2006). doi:10.1158/0008-5472.CAN-06-2554. PMID17145850.
“Negative regulation of the serine/threonine kinase B-Raf by Akt”. The Journal of Biological Chemistry275 (35): 27354–9. (September 2000). doi:10.1074/jbc.M004371200. PMID10869359.
“Active Ras induces heterodimerization of cRaf and BRaf”. Cancer Research61 (9): 3595–8. (May 2001). PMID11325826.
“Biochemical analysis of MEK activation in NIH3T3 fibroblasts. Identification of B-Raf and other activators”. The Journal of Biological Chemistry270 (13): 7644–55. (March 1995). doi:10.1074/jbc.270.13.7644. PMID7706312.
“Cell type-specific regulation of B-Raf kinase by cAMP and 14-3-3 proteins”. The Journal of Biological Chemistry275 (41): 31921–9. (October 2000). doi:10.1074/jbc.M003327200. PMID10931830.